# Accropeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/accropeutics

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.accropeutics.com/
- Total disclosed funding: $114M
- Latest round: Series C (May 18, 2026)
- Investors on record: 13

## About

Based in Suzhou, China and founded in 2017, Accropeutics operates as a provider of small molecule innovative medicine that focuses on the research and development of necroptosis inhibitor. The company has acquired more than 10 patents, and has been rated as a Technology-based SMEs. The Co-founder and CEO, Zhang Xiaohu, received a Ph.D. in Chemistry from the State University of New Jersey and worked at Neurocrine Biosciences. The Co-founder, He Sudan, received a Ph.D. in Biochemistry and Molecular Biology from Peking Union Medical College. She was a professor at Soochow University and a researcher at the Suzhou Institute of Systems Medicine.

Accropeutics is mainly engaged in the research and development of necroptosis inhibitor. The core technology is a new drug development platform targeting regulated cell death. Products include RIPK1 inhibitor AC-003, RIPK2 inhibitor AC-101, highly selective TYK2/JAK1 inhibitor AC-201, etc. Its platform and products focus on diseases such as inflammation, fibrosis, autoimmune diseases and cancer.

The company generates revenue by providing new medicines for the treatment of inflammation, fibrosis, autoimmune diseases and cancer.

The company will use the series B+ funding to accelerate clinical-stage drug development for inflammatory and autoimmune diseases such as inflammatory bowel disease, psoriasis, non-infectious uveitis and acute graft-versus-host disease.  In May 2026, Accropeutics raised USD 50 million in series C funding led by new investor OrbiMed, with participation from other new investors TCG Crossover Management, LAV, and Cenova Ventures. Returning investors Shenzhen Capital Real Estate Fund and Oriza Holdings also participated in the round.

## Funding rounds

- Series C, May 18, 2026, $50M — OrbiMed Advisors, Oriza Holdings, Cenova Ventures, Shenzhen Capital Real Estate Fund, TCG Crossover Management, LAV
- Series B, Mar 14, 2025, $14M — Shenzhen Capital Real Estate Fund, Leader Venture Capital, Hefei Innovation Investment, Morningside Ventures
- Series B, Jan 5, 2022, $50M — Oriza Holdings, GF Xinde Investment, Hongtai Aplus, South China Venture Capital, Shenzhen Capital Real Estate Fund, Sanhhua Hongdao Capital

## Investors

- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series B, Series C
- GF Xinde Investment (https://capitalatlas.ai/funds/gf-xinde-investment) — Series B
- Hongtai Aplus (https://capitalatlas.ai/funds/hongtai-aplus) — Series B
- South China Venture Capital (https://capitalatlas.ai/funds/south-china-venture-capital) — Series B
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series B, Series C
- Sanhhua Hongdao Capital (https://capitalatlas.ai/funds/sanhhua-hongdao-capital) — Series B
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series B
- Hefei Innovation Investment — Series B
- Morningside Ventures — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Cenova Ventures (https://capitalatlas.ai/funds/cenova-ventures) — Series C
- TCG Crossover Management (https://capitalatlas.ai/funds/tcg-crossover-management) — Series C
- LAV (https://capitalatlas.ai/funds/lav) — Series C